Retatrutide Phase 3 Trial Shows Significant Weight Loss and Health Benefits
In a significant advancement for obesity treatment, researchers have reported that retatrutide, an experimental weekly injection, led to an average weight loss of 25% among participants at the highest dose over an 80-week period. The findings were published in The New England Journal of Medicine and indicate not only weight loss but also improvements in associated health issues such as knee pain and sleep apnea. The trial, conducted by a team led by obesity researcher Ania Jastreboff at Yale University, enrolled 2,339 adults with obesity but without diabetes. Participants were randomly assigned to receive weekly injections of either 4, 9, or 12 milligrams of retatrutide or a placebo. The study was designed to evaluate the drug's effects on weight loss and related health complications, rather than solely focusing on weight reduction. The results showed that those receiving the highest dose of retatrutide experienced a reduction in knee pain and a significant decrease in sleep apnea events compared to the placebo group. Specifically, participants with knee osteoarthritis reported an average pain score decrease of 4.1 points on a 0–10 scale with the 12-milligram dose, while those suffering from obstructive sleep apnea saw a reduction in episodes of stopped or shallow breathing by an average of 32.1 per hour. The study's design allowed for a comprehensive understanding of retatrutide's impact over time, with a smaller group followed for two years showing an average weight loss approaching 30%. However, the trial also highlighted the presence of side effects, primarily gastrointestinal issues, with 42% of participants in the highest-dose group reporting nausea. Serious adverse events were noted in 10.5% of the retatrutide group compared to 5.5% in the placebo group. While the data is promising, the trial was not structured to establish cardiovascular safety, and further research is necessary to compare retatrutide's efficacy directly with existing obesity medications like semaglutide and tirzepatide. The findings underscore the potential of retatrutide in addressing obesity and its related health challenges, but they also emphasize the importance of ongoing research to fully understand the drug's safety and effectiveness in diverse populations.




